Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) have been given an average rating of “Hold” by the twenty-five ratings firms that are covering the company, American Banking News.com reports. Twelve analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $18.71.
Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at 15.33 on Monday. Allscripts Healthcare Solutions has a one year low of $12.54 and a one year high of $19.68. The stock’s 50-day moving average is $17.59 and its 200-day moving average is $16.15. The company’s market cap is $2.745 billion.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $351.00 million for the quarter, compared to the consensus estimate of $343.47 million. Analysts expect that Allscripts Healthcare Solutions will post $0.40 EPS for the current fiscal year.
A number of research firms have recently commented on MDRX. Analysts at Ned Davis Research upgraded shares of Allscripts Healthcare Solutions from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of Allscripts Healthcare Solutions in a research note on Tuesday, April 15th. They now have a $19.00 price target on the stock. Finally, analysts at SunTrust initiated coverage on shares of Allscripts Healthcare Solutions in a research note on Friday, March 14th. They set a “buy” rating and a $22.50 price target on the stock.
Allscripts Healthcare Solutions, Inc (NASDAQ:MDRX) is a provider of clinical, financial, connectivity and information solutions and related professional services to hospitals, physicians and post-acute organizations.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.